Results of ATTAIN-1 and STEP UP Phase 3 Trials
Sep 25, 01:00 AM
Share
Subscribe
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!
In this episode, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospital Diabetes and Metabolic Care Center, discuss the recently published results of the ATTAIN-1 and STEP UP clinical trials, both of which were presented at the European Association for the Study of Diabetes (EASD) 2025 Conference.
00:00:00 Introduction
00:00:32 ATTAIN-1
00:04:07 GLP-1s as a Daily Pill
00:08:20 Possible Lower GLP-1 Prices
00:09:03 STEP UP
00:11:41 Cardiovascular Protection with GLP-1s
00:12:48 GI Side Effects of Semaglutide 7.2
00:16:16 3 Times the Dose, 3 Times the Cardiovascular Protection?
00:17:20 Outro
In this episode, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospital Diabetes and Metabolic Care Center, discuss the recently published results of the ATTAIN-1 and STEP UP clinical trials, both of which were presented at the European Association for the Study of Diabetes (EASD) 2025 Conference.
00:00:00 Introduction
00:00:32 ATTAIN-1
00:04:07 GLP-1s as a Daily Pill
00:08:20 Possible Lower GLP-1 Prices
00:09:03 STEP UP
00:11:41 Cardiovascular Protection with GLP-1s
00:12:48 GI Side Effects of Semaglutide 7.2
00:16:16 3 Times the Dose, 3 Times the Cardiovascular Protection?
00:17:20 Outro